TCIM
PTLA

TIAA CREF Investment Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

TIAA CREF Investment Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4M Sell
115,135
-3,364
-3% -$97.1K ﹤0.01% 1589
2018
Q4 		$2.31M Sell
118,499
-5,872
-5% -$121K ﹤0.01% 1868
2018
Q3 		$3.31M Sell
124,371
-51,978
-29% -$1.7M ﹤0.01% 1857
2018
Q2 		$6.66M Sell
176,349
-25,804
-13% -$987K ﹤0.01% 1406
2018
Q1 		$6.6M Sell
202,153
-19,384
-9% -$851K ﹤0.01% 1383
2017
Q4 		$10.8M Buy
221,537
+5,061
+2% +$256K 0.01% 1095
2017
Q3 		$11.7M Buy
216,476
+2,284
+1% +$134K 0.01% 1050
2017
Q2 		$12M Sell
214,192
-9,732
-4% -$390K 0.01% 1026
2017
Q1 		$8.78M Buy
223,924
+8,673
+4% +$276K 0.01% 1207
2016
Q4 		$4.83M Sell
215,251
-23,696
-10% -$463K ﹤0.01% 1629
2016
Q3 		$5.43K Buy
238,947
+5,370
+2% +$126K ﹤0.01% 1554
2016
Q2 		$5.51M Buy
233,577
+16,445
+8% +$406K ﹤0.01% 1472
2016
Q1 		$4.43M Buy
217,132
+23,190
+12% +$736K ﹤0.01% 1583
2015
Q4 		$9.98M Buy
193,942
+5,859
+3% +$284K 0.01% 1071
2015
Q3 		$8.02M Sell
188,083
-8,483
-4% -$409K 0.01% 1186
2015
Q2 		$8.95M Sell
196,566
-6,396
-3% -$257K 0.01% 1232
2015
Q1 		$7.7M Buy
202,962
+2,990
+1% +$103K 0.01% 1330
2014
Q4 		$5.66M Buy
199,972
+10,057
+5% +$280K ﹤0.01% 1544
2014
Q3 		$4.8M Buy
189,915
+4,786
+3% +$126K ﹤0.01% 1643
2014
Q2 		$5.4M Buy
185,129
+100,100
+118% +$2.42M ﹤0.01% 1644
2014
Q1 		$2.2M Buy
85,029
+10,169
+14% +$271K ﹤0.01% 2186
2013
Q4 		$1.93M Buy
74,860
+30,560
+69% +$743K ﹤0.01% 2276
2013
Q3 		$1.19M Buy
44,300
+5,348
+14% +$127K ﹤0.01% 2519
2013
Q2 		$957K Buy
+38,952
New +$774K ﹤0.01% 2609

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

TIAA CREF Investment Management's PTLA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Portola Pharmaceuticals, Inc. (PTLA) stake by 2.8% in Q1 2019, selling an estimated $97.1K and leaving 115,135 shares worth $4M. The position accounts for ﹤0.01% of the portfolio, ranked #1589.

TIAA CREF Investment Management first reported a position in PTLA in Q2 2013 and has held it in 24 quarters since. The position peaked at $12M in Q2 2017. 209 funds tracked by Wall St. Rank hold PTLA as of Q1 2019.

  • TIAA CREF Investment Management held 115,135 shares of Portola Pharmaceuticals, Inc. worth $4M as of Q1 2019.
  • TIAA CREF Investment Management sold 3,364 Portola Pharmaceuticals, Inc. shares in Q1 2019, an estimated $97.1K.
  • Portola Pharmaceuticals, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1589 holding.
  • TIAA CREF Investment Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Portola Pharmaceuticals, Inc. position peaked at $12M in Q2 2017.
  • 209 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.